NZ598703A - Modification of recombinant adenovirus with immunogenic plasmodium circumsporozoite protein epitopes - Google Patents
Modification of recombinant adenovirus with immunogenic plasmodium circumsporozoite protein epitopesInfo
- Publication number
- NZ598703A NZ598703A NZ598703A NZ59870310A NZ598703A NZ 598703 A NZ598703 A NZ 598703A NZ 598703 A NZ598703 A NZ 598703A NZ 59870310 A NZ59870310 A NZ 59870310A NZ 598703 A NZ598703 A NZ 598703A
- Authority
- NZ
- New Zealand
- Prior art keywords
- recombinant adenovirus
- nanp
- plasmodium circumsporozoite
- protein gene
- plasmid vector
- Prior art date
Links
- 241000701161 unidentified adenovirus Species 0.000 title abstract 7
- 108700005482 Protozoan circumsporozoite Proteins 0.000 title abstract 5
- 230000002163 immunogen Effects 0.000 title abstract 4
- 230000004048 modification Effects 0.000 title 1
- 238000012986 modification Methods 0.000 title 1
- KQPKMEYBZUPZGK-UHFFFAOYSA-N 4-[(4-azido-2-nitroanilino)methyl]-5-(hydroxymethyl)-2-methylpyridin-3-ol Chemical compound CC1=NC=C(CO)C(CNC=2C(=CC(=CC=2)N=[N+]=[N-])[N+]([O-])=O)=C1O KQPKMEYBZUPZGK-UHFFFAOYSA-N 0.000 abstract 6
- 101001111984 Homo sapiens N-acylneuraminate-9-phosphatase Proteins 0.000 abstract 6
- 102100023906 N-acylneuraminate-9-phosphatase Human genes 0.000 abstract 6
- 101710132601 Capsid protein Proteins 0.000 abstract 5
- 108090000565 Capsid Proteins Proteins 0.000 abstract 4
- 210000000234 capsid Anatomy 0.000 abstract 4
- 239000013600 plasmid vector Substances 0.000 abstract 4
- 230000000890 antigenic effect Effects 0.000 abstract 2
- 239000002773 nucleotide Substances 0.000 abstract 2
- 125000003729 nucleotide group Chemical group 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 210000003719 b-lymphocyte Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
- A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
- C07K14/445—Plasmodium
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/04—Inactivation or attenuation; Producing viral sub-units
- C12N7/045—Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2009/054212 WO2011022002A1 (en) | 2009-08-18 | 2009-08-18 | Modification of recombinant adenovirus with immunogenic plasmodium circumsporozoite protein epitopes |
| PCT/US2010/045952 WO2011022522A1 (en) | 2009-08-18 | 2010-08-18 | Modification of recombinant adenovirus with immunogenic plasmodium circumsporozoite protein epitopes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ598703A true NZ598703A (en) | 2014-04-30 |
Family
ID=43607237
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ598703A NZ598703A (en) | 2009-08-18 | 2010-08-18 | Modification of recombinant adenovirus with immunogenic plasmodium circumsporozoite protein epitopes |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20170348405A1 (https=) |
| EP (2) | EP3412306A3 (https=) |
| JP (2) | JP5947719B2 (https=) |
| KR (1) | KR20120094469A (https=) |
| CN (2) | CN105770880A (https=) |
| BR (1) | BR112012003808A2 (https=) |
| CA (1) | CA2769415A1 (https=) |
| IL (1) | IL217709A (https=) |
| MX (1) | MX339830B (https=) |
| NZ (1) | NZ598703A (https=) |
| PH (1) | PH12012500164A1 (https=) |
| RU (1) | RU2585228C2 (https=) |
| SG (2) | SG178476A1 (https=) |
| UA (1) | UA108081C2 (https=) |
| WO (2) | WO2011022002A1 (https=) |
| ZA (1) | ZA201201286B (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012154199A1 (en) | 2010-10-18 | 2012-11-15 | The Government Of The United States, As Represented By The Secretary Of The Army | Soluble recombinant plasmodium falciparum circumsporozoite protein |
| US20120244178A1 (en) * | 2011-03-25 | 2012-09-27 | Denise Doolan | Plasmodium falciparum antigens |
| AU2014236207B2 (en) | 2013-03-14 | 2019-05-23 | Salk Institute For Biological Studies | Oncolytic adenovirus compositions |
| WO2014196648A1 (en) * | 2013-06-03 | 2014-12-11 | Vlp Therapeutics, Llc | Malaria vaccine |
| KR20250081944A (ko) | 2014-09-24 | 2025-06-05 | 솔크 인스티튜트 포 바이올로지칼 스터디즈 | 종양 살상 바이러스 및 이의 사용방법 |
| WO2017048689A1 (en) * | 2015-09-16 | 2017-03-23 | Artificial Cell Technologies, Inc. | Anti-malaria compositions and methods |
| US10517938B2 (en) | 2016-01-21 | 2019-12-31 | Janssen Vaccines & Prevention B.V. | Adenovirus based malaria vaccine encoding and displaying a malaria antigen |
| EP4155411A1 (en) | 2016-02-23 | 2023-03-29 | Salk Institute for Biological Studies | Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics |
| WO2017147265A1 (en) | 2016-02-23 | 2017-08-31 | Salk Institute For Biological Studies | High throughput assay for measuring adenovirus replication kinetics |
| CN107841513B (zh) * | 2016-09-18 | 2023-04-14 | 中国科学院上海巴斯德研究所 | 基于M2e表位的广谱型流感疫苗 |
| EP3532082A4 (en) | 2016-12-12 | 2020-08-26 | Salk Institute for Biological Studies | SYNTHETIC ADENOVIRUS TUMOR TARGETING AND THEIR USES |
| CN108192876A (zh) * | 2017-12-07 | 2018-06-22 | 东莞市第八人民医院 | 一种人3型腺病毒衣壳蛋白同时展示ca16双中和抗原表位疫苗候选株的制备方法和应用 |
| MX2020010499A (es) | 2018-04-09 | 2020-10-28 | Salk Inst For Biological Studi | Composiciones de adenovirus oncoliticas con propiedades aumentadas de replicacion. |
| WO2020221451A1 (en) * | 2019-04-30 | 2020-11-05 | Humabs Biomed Sa | Antibodies binding to plasmodium circumsporozoite protein and uses thereof |
| CN110687289B (zh) * | 2019-10-17 | 2023-04-18 | 中国人民解放军陆军军医大学 | Fgl2蛋白作为疟疾感染标志物的应用 |
| GB201915905D0 (en) * | 2019-11-01 | 2019-12-18 | Spybiotech Ltd | Viruses with modified capsid proteins |
| JP2021178021A (ja) * | 2020-05-14 | 2021-11-18 | 株式会社三洋物産 | 遊技機 |
| WO2022234276A1 (en) * | 2021-05-04 | 2022-11-10 | SpyBiotech Limited | Adenoviral vectors and vaccines thereof |
| EP4404947A4 (en) * | 2021-09-23 | 2025-12-10 | Sagittarius Bio Inc | Adenovirus and Methods of Using Adenovirus |
| CN120944926B (zh) * | 2025-10-15 | 2026-01-30 | 华中科技大学同济医学院附属同济医院 | 衣壳表面展示超大片段抗原的重组腺病毒、构建方法及应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6066623A (en) * | 1993-11-23 | 2000-05-23 | The United States Of America As Represented By The Secretary Of The Navy | Polynucleotide vaccine protective against malaria, methods of protection and vector for delivering polynucleotide vaccines |
| CN1561389A (zh) * | 2001-07-25 | 2005-01-05 | 纽约大学 | 糖基神经酰胺作为用于抗传染病和癌症的疫苗的佐剂的用途 |
| CA2502268A1 (en) * | 2002-10-23 | 2004-05-06 | Glaxosmithkline Biologicals S.A. | Methods for vaccinating against malaria |
| WO2004055187A1 (en) * | 2002-12-17 | 2004-07-01 | Crucell Holland B.V. | Recombinant viral-based malaria vaccines |
| US7611868B2 (en) * | 2003-05-14 | 2009-11-03 | Instituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Recombinant modified adenovirus fiber protein |
| JP2005287309A (ja) * | 2004-03-31 | 2005-10-20 | Dnavec Research Inc | 遺伝子導入を増強するための薬剤および方法 |
| JP4843613B2 (ja) * | 2004-10-13 | 2011-12-21 | クルセル ホランド ベー ヴェー | 改良されたアデノウイルスベクターおよびその使用方法 |
| AU2006284756B2 (en) * | 2005-08-31 | 2012-06-07 | Genvec, Inc. | Adenoviral vector-based malaria vaccines |
| WO2008140474A1 (en) * | 2006-10-26 | 2008-11-20 | Johns Hopkins University | Recombinant adenovirus vaccines |
-
2009
- 2009-08-18 WO PCT/US2009/054212 patent/WO2011022002A1/en not_active Ceased
-
2010
- 2010-08-18 CN CN201510745347.3A patent/CN105770880A/zh active Pending
- 2010-08-18 CA CA2769415A patent/CA2769415A1/en not_active Abandoned
- 2010-08-18 EP EP18168155.2A patent/EP3412306A3/en not_active Withdrawn
- 2010-08-18 MX MX2012002131A patent/MX339830B/es active IP Right Grant
- 2010-08-18 CN CN201080047059.6A patent/CN103025349B/zh not_active Expired - Fee Related
- 2010-08-18 WO PCT/US2010/045952 patent/WO2011022522A1/en not_active Ceased
- 2010-08-18 JP JP2012525677A patent/JP5947719B2/ja not_active Expired - Fee Related
- 2010-08-18 UA UAA201203125A patent/UA108081C2/ru unknown
- 2010-08-18 NZ NZ598703A patent/NZ598703A/en not_active IP Right Cessation
- 2010-08-18 EP EP10810576.8A patent/EP2467157A4/en not_active Withdrawn
- 2010-08-18 PH PH1/2012/500164A patent/PH12012500164A1/en unknown
- 2010-08-18 SG SG2012011144A patent/SG178476A1/en unknown
- 2010-08-18 RU RU2012110255/10A patent/RU2585228C2/ru not_active IP Right Cessation
- 2010-08-18 KR KR1020127006889A patent/KR20120094469A/ko not_active Ceased
- 2010-08-18 BR BR112012003808A patent/BR112012003808A2/pt not_active IP Right Cessation
- 2010-08-18 SG SG10201404970PA patent/SG10201404970PA/en unknown
-
2012
- 2012-01-24 IL IL217709A patent/IL217709A/en not_active IP Right Cessation
- 2012-02-21 ZA ZA2012/01286A patent/ZA201201286B/en unknown
-
2016
- 2016-03-03 JP JP2016041230A patent/JP6293181B2/ja not_active Expired - Fee Related
-
2017
- 2017-01-30 US US15/419,523 patent/US20170348405A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| RU2012110255A (ru) | 2013-09-27 |
| JP5947719B2 (ja) | 2016-07-06 |
| JP6293181B2 (ja) | 2018-03-14 |
| MX2012002131A (es) | 2012-04-11 |
| EP3412306A2 (en) | 2018-12-12 |
| MX339830B (es) | 2016-06-13 |
| KR20120094469A (ko) | 2012-08-24 |
| ZA201201286B (en) | 2013-05-29 |
| CN103025349A (zh) | 2013-04-03 |
| CN103025349B (zh) | 2016-05-18 |
| EP3412306A3 (en) | 2019-01-02 |
| BR112012003808A2 (pt) | 2016-11-16 |
| UA108081C2 (uk) | 2015-03-25 |
| JP2016146837A (ja) | 2016-08-18 |
| IL217709A (en) | 2016-05-31 |
| WO2011022002A1 (en) | 2011-02-24 |
| US20170348405A1 (en) | 2017-12-07 |
| WO2011022522A1 (en) | 2011-02-24 |
| HK1179508A1 (zh) | 2013-10-04 |
| EP2467157A1 (en) | 2012-06-27 |
| CN105770880A (zh) | 2016-07-20 |
| CA2769415A1 (en) | 2011-02-24 |
| SG10201404970PA (en) | 2014-10-30 |
| JP2013502221A (ja) | 2013-01-24 |
| IL217709A0 (en) | 2012-03-29 |
| RU2585228C2 (ru) | 2016-05-27 |
| EP2467157A4 (en) | 2014-01-22 |
| AU2010286187A1 (en) | 2012-02-16 |
| SG178476A1 (en) | 2012-03-29 |
| PH12012500164A1 (en) | 2022-03-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ598703A (en) | Modification of recombinant adenovirus with immunogenic plasmodium circumsporozoite protein epitopes | |
| JP2016146837A5 (https=) | ||
| MX2013014109A (es) | Proteina de fusion que comprende el mutante crm197 no toxico de toxina de difteria. | |
| MX2015014720A (es) | Mutante de epimerasa psicosa y metodo para preparar psicosa mediante el uso del mismo. | |
| WO2009130588A3 (en) | Codon-optimzed hepatitis b virus core antigen (hbcag) | |
| MX2013010620A (es) | Adenovirus de aves del serotipo 4 (fadv-4) no patogénico y vector viral del mismo. | |
| NZ608143A (en) | Recombinant modified vaccinia virus ankara (mva) influenza vaccine | |
| MX377650B (es) | Vacuna y métodos para reducir una infección por campylobacter. | |
| CL2012000452A1 (es) | Acido nucleico infeccioso de virus torque teno porcino (pttv), que comprende secuencia que codifica un pttv infeccioso con una secuencia genomica de pttv 1a-va; acido nucleico, plasmido y celula hospedera que la comprenden; pttv infeccioso no virulento; vacuna. | |
| CO6150189A2 (es) | Vacunas para malaria | |
| AU2023258457B2 (en) | Live-attenuated flaviruses with heterologous antigens | |
| MY163972A (en) | Attenuated recombinant newcastle disease virus and vaccine containing the same | |
| PH12020500526A1 (en) | Paramyxoviridae expression system | |
| CN103923943B (zh) | 一种基于腺病毒AdC7的表达载体及其构建方法 | |
| NZ603431A (en) | Parapoxvirus vectors containing rabies virus antigen | |
| NZ596223A (en) | Combined measles-malaria vaccine | |
| CN101914566B (zh) | 基于E2基因的可插入式猪瘟病毒cDNA载体构建及应用 | |
| US20210122787A1 (en) | Tetravalent dengue vaccine | |
| WO2010009465A3 (en) | Htlv-ii vector and methods of use | |
| WO2007115385A3 (en) | Transfer plasmidic vector and recombinant canarypox virus | |
| BR0012556A (pt) | Genes e vacinas de ehrlichia canis | |
| HK40032428A (en) | Vaccine | |
| WO2010127420A9 (pt) | Sequências geneticamente modificadas de antígenos de plasmodium vivax | |
| HE et al. | Study on the complex hepatitis C virus antigen with multi-genotype E1 epitopes | |
| XIE et al. | Immunogenicity of DNA vaccines encoding regulatory/accessory proteins derived from three different prevalent strains in China |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 18 AUG 2017 BY DAVIES COLLISON CAVE Effective date: 20140804 |
|
| LAPS | Patent lapsed |